Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)
Gilead Sciences (GILD) reported Income from Non-Controlling Interests of -$12.0 million for Q4 2023, down 71.43% on a YoY basis from -$42.0 million in Q4 2022, and down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023.
Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends
Gilead Sciences has reported Income from Non-Controlling Interests for 15 years, with the latest figure at -$12.0 million in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million; the trailing twelve-month figure through Sep 2024 stood at -$12.0 million (up 74.47% YoY), and the FY2023 full-year result was -$52.0 million, down 100.0% from the prior year.
- Income from Non-Controlling Interests for Q4 2023 stood at -$12.0 million, down from -$8.0 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$3.0 million in Q3 2019, with the low at -$26.0 million in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged -$7.9 million across 5 years, with a median of -$7.0 million in 2019.
- Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests plunged 800.0% — and 2022, when it jumped 50.0%.
- Gilead Sciences' Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then increased by 14.29% to -$6.0 million in 2021, then fell by 16.67% to -$7.0 million in 2022, then sank by 71.43% to -$12.0 million in 2023.
- The last three Income from Non-Controlling Interests figures came in at -$12.0 million (Q4 2023), -$8.0 million (Q3 2023), and -$6.0 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | 415.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.00 Mn |
| Jun 30, 2023 | -6.00 Mn |
| Mar 31, 2023 | -26.00 Mn |
| Dec 31, 2022 | -7.00 Mn |
| Sep 30, 2022 | -3.00 Mn |
| Jun 30, 2022 | -9.00 Mn |
| Mar 31, 2022 | -7.00 Mn |
| Dec 31, 2021 | -6.00 Mn |
| Sep 30, 2021 | -6.00 Mn |
| Jun 30, 2021 | -5.00 Mn |
| Mar 31, 2021 | -7.00 Mn |
| Dec 31, 2020 | -7.00 Mn |
| Sep 30, 2020 | -7.00 Mn |
| Jun 30, 2020 | -7.00 Mn |
| Mar 31, 2020 | -13.00 Mn |
| Dec 31, 2019 | -7.00 Mn |
| Sep 30, 2019 | -3.00 Mn |
| Jun 30, 2019 | -5.00 Mn |
| Mar 31, 2019 | -7.00 Mn |